Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced preliminary, unaudited financial results for the fourth
quarter and year ended December 31, 2023.
Preliminary, Unaudited Full-Year 2023 Financial
Results
- Total net revenue expected to be approximately $197.5 million,
representing 20% growth
- MACI® net revenue expected to be
approximately $164.8 million, representing 25% growth
- Burn Care net revenue expected to be
approximately $32.7 million, consisting of approximately $31.6
million of Epicel® revenue and $1.1 million of NexoBrid®
revenue
- Gross margin expected to be in the
high-60% range
- Adjusted EBITDA margin expected to be
in the mid-teens percentage range, with full-year adjusted EBITDA
growth expected to be approximately 30%
- As of December 31,
2023, the Company had approximately $152 million in cash,
restricted cash and investments and no debt
Preliminary, Unaudited Fourth Quarter Financial Results
and Commercial Highlights
- Total net revenue expected to be approximately $65.0 million,
representing 23% growth
- MACI net revenue expected to be
approximately $56.7 million, representing 22% growth, marking the
sixth straight quarter of 20%+ MACI growth
- Burn Care net revenue expected to be
approximately $8.3 million, representing 31% growth, consisting of
approximately $7.8 million of Epicel revenue and $0.5 million of
NexoBrid revenue
- Positive adjusted EBITDA and Operating
Cash Flow expected for the 14th straight quarter
- Gross margin expected to be greater
than 70%
- Adjusted EBITDA margin expected to be
approximately 30%
- Highest number of MACI implants, implanting surgeons, surgeons
taking biopsies and MACI biopsies in a quarter since launch
- Highest number of Epicel biopsies in a quarter since 2021
- NexoBrid commercial launch in the U.S., with over 50 burn
centers submitting packages to Pharmacy and Therapeutics (P&T)
committees and over 25 burn centers with P&T committee
approvals
“The Company had a very strong close to the year with
outstanding fourth quarter financial results driven by high revenue
growth in both of our franchises and strong business fundamentals
across our portfolio,” said Nick Colangelo, President and CEO of
Vericel. “We enter 2024 with a great deal of momentum and expect
another year of high revenue growth and increasing profitability
driven by continued strong execution with our core products, a full
year of NexoBrid on the U.S. market and the anticipated launch of
arthroscopic MACI later this year.”
Vericel is scheduled to present at the 42nd Annual J.P. Morgan
Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday,
January 10, 2024. A webcast of the presentation will be available
on the Investor Relations section of the Vericel Corporation
website at: http://investors.vcel.com.
About Vericel Corporation Vericel is a leading
provider of advanced therapies for the sports medicine and severe
burn care markets. The Company combines innovations in biology
with medical technologies, resulting in a highly differentiated
portfolio of innovative cell therapies and specialty biologics that
repair injuries and restore lives. Vericel markets three products
in the United States. MACI (autologous cultured chondrocytes on
porcine collagen membrane) is an autologous cellularized scaffold
product indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. Vericel also holds an exclusive license
for North American rights to NexoBrid (anacaulase-bcdb), a
biological orphan product containing proteolytic enzymes, which is
indicated for the removal of eschar in adults with deep
partial-thickness and/or full-thickness burns. For more
information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2024 Vericel
Corporation. All rights reserved.
Preliminary and Unaudited Nature of Reported
ResultsOur revenue expectations for the fourth quarter and
full-year ended 2023, as well as our estimates concerning adjusted
EBITDA, operating cash flows, cash, restricted cash and investments
are preliminary, unaudited and are subject to change based on the
completion of ongoing internal control, review, and audit
procedures. As a result, these amounts may differ materially from
the amounts that will be reflected in the Company’s consolidated
financial statements for the year ended December 31, 2023.
Accordingly, you should not place undue reliance on this
preliminary estimate.
GAAP v. Non-GAAP MeasuresVericel has provided
in this release certain financial information that has not been
prepared in accordance with generally accepted accounting
principles in the United States, or GAAP. Vericel’s management
believes that the non-GAAP adjusted EBITDA described in the
release, which includes adjustments for specific items that are
generally not indicative of our core operations, provides
additional information that is useful to investors in understanding
Vericel’s underlying performance, business and performance trends,
and helps facilitate period-to-period comparisons and comparisons
of its financial measures with other companies in Vericel’s
industry. However, the non-GAAP financial measures that Vericel
uses may differ from measures that other companies may
use. Non-GAAP financial measures are not required to be
uniformly applied, are not audited and should not be considered in
isolation or as substitutes for results prepared in accordance with
GAAP.
Forward-Looking StatementsVericel cautions you
that all statements other than statements of historical fact
included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may
occur in the future are forward-looking statements. Although we
believe that we have a reasonable basis for the forward-looking
statements contained herein, they are based on current expectations
about future events affecting us and are subject to risks,
assumptions, uncertainties and factors relating to our operations
and business environment, all of which are difficult to predict and
many of which are beyond our control. Our actual results may differ
materially from those expressed or implied by the forward-looking
statements in this press release. These statements are often, but
are not always, made through the use of words or phrases such as
“anticipates,” “intends,” “estimates,” “plans,” “expects,”
“continues,” “believe,” “guidance,” “outlook,” “target,” “future,”
“potential,” “goals” and similar words or phrases, or future or
conditional verbs such as “will,” “would,” “should,” “could,”
“may,” or similar expressions.
Among the factors that could cause actual results to differ
materially from those set forth in the forward-looking statements
include, but are not limited to, the inherent uncertainties
associated with our expectations concerning expected revenue
results for the fourth quarter and full-year ended 2023, adjusted
EBITDA, operating cash flow, and estimates of our cash, restricted
cash and investments as of December 31, 2023. Vericel’s revenue
expectations for the fourth quarter and full-year ended 2023, as
well as its estimates concerning adjusted EBITDA, operating cash
flow, and cash, restricted cash and investments are preliminary,
unaudited and are subject to change during ongoing internal
control, review, and audit procedures. Additional factors that
could cause actual results to differ materially from those set
forth in the forward-looking statements include, but are not
limited to, uncertainties associated with our expectations
regarding future revenue, growth in revenue, market penetration for
MACI, Epicel, and NexoBrid, growth in profit, gross margins and
operating margins, the ability to continue to scale our
manufacturing operations to meet the demand for our cell therapy
products, including the timely completion of a new headquarters and
manufacturing facility in Burlington, Massachusetts, the ability to
achieve or sustain profitability, contributions to adjusted EBITDA,
the expected target surgeon audience, potential fluctuations in
sales and volumes and our results of operations over the course of
the year, timing and conduct of clinical trial and product
development activities, timing and likelihood of the FDA’s
potential approval of the arthroscopic delivery of MACI to the knee
or the use of MACI to treat cartilage defects in the ankle, the
estimate of the commercial growth potential of our products and
product candidates, competitive developments, changes in
third-party coverage and reimbursement, physician and burn center
adoption of NexoBrid, supply chain disruptions or other events or
factors affecting MediWound’s ability to manufacture and supply
sufficient quantities of NexoBrid to meet customer demand,
including but not limited to the ongoing Israel-Hamas war, negative
impacts on the global economy and capital markets resulting from
the conflict in Ukraine and the Israel-Hamas war, adverse
developments affecting financial institutions, companies in the
financial services industry or the financial services industry
generally, global geopolitical tensions or record inflation and
potential future impacts on our business or the economy generally
stemming from a resurgence of COVID-19 or another similar public
health emergency.
These and other significant factors are discussed in greater
detail in Vericel’s Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the Securities and Exchange
Commission (SEC) on February 23, 2023, Vericel’s Quarterly Report
on Form 10-Q for the quarter ended September 30, 2023, filed with
the SEC on November 8, 2023, and in other filings with the SEC.
These forward-looking statements reflect our views as of the date
hereof and Vericel does not assume and specifically disclaims any
obligation to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024